🔗 Share this article

While the US proceeds with historic adjustments to its immunization recommendations, one figure has surfaced somewhat surprisingly: Tracy Beth Høeg, an American of Danish descent sports physician and public health researcher who rose to prominence by expressing skepticism about COVID-19 vaccinations throughout the global health crisis and has focused upon alleged fatalities after COVID-19 immunization in her brief time at the US Food and Drug Administration (FDA).

Proposed Changes to Childhood Vaccine Program

Agency leaders were set to unveil major revisions to the pediatric vaccine schedule recently, synchronizing the US with Denmark’s immunization schedule, it is understood – a major change that would put the US out of alignment with many the world with no evidence for public health gain. The planned update has been pushed back until the next year.

Rather than the director of the vaccine center, Dr. Høeg is scheduled to address the audience at the gathering. She was recently named temporary leader of the FDA’s drug evaluation center, the fifth individual to head the office this calendar year.

A Shift at the Regulatory Body

The acting appointment may indicate a closer partnership between the drug and vaccine branches as Dr. Høeg and Dr. Prasad solidify control at the agency – and it points to a increased emphasis upon rolling back already-approved vaccines at the FDA.

The new acting director has often pushed for discontinuing certain childhood immunization guidelines in the US so as to align more similar to the Danish model, a country with comprehensive healthcare and a population about the population of the state of Wisconsin.

In her initial comments, she has kept her attention on vaccines – usually the purview of Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – rather than drug regulation.

Doubts Over Background

Høeg has no obvious experience in pharmaceutical research, approval processes or leadership, which has been typical for previous directors of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a top consultant to the agency head and the vaccine center since earlier this year.

“She appears not to have the requisite experience” for running the drug-regulation department, remarked Jonathan Howard. “She has not conducted a randomized controlled trial. She is not versed in running a major agency. She is not an expert in drug approvals.”

Past commissioners of the center would “understand laws and regulations and the science of medication creation”, said a former acting FDA commissioner. “Objectively, she has not acquired the type of experience that previous people who ran the center have had.”

The drug center has an vast portfolio at the agency, the former commissioner stated.

“Everybody just zeroes in on the novel medication approvals, but the off-patent medication office authorizes numerous off-brand pharmaceuticals. There’s a biosimilars division, over-the-counter program and more, and each of these have to be supervised,” Woodcock noted. “The thing you overlook, that is precisely what that I always told people is going to cause problems.”

Furthermore, a major administrative aspect to the position, which manages more than 5,000 employees. “It’s a enormous administrative position, if you do it right,” Woodcock concluded.

Response and Controversial Programs

When asked about inquiries about Dr. Høeg's fitness for the role and whether this assignment signifies greater collaboration among regulatory chiefs on vaccines, a representative stated that the “concerns are based on flawed premises”.

“Her resume matches the functions of her position,” the representative explained, noting the period Høeg spent guiding the FDA commissioner on “pharmaceutical safety and approval science, including computerized risk analysis and shot safety tracking”.

In her interim role, Høeg assumes responsibility for the commissioner’s new expedited review system, a contentious one-day medication authorization process that apparently worried her predecessors. “How are these medications being selected for this expedited pathway? Who makes the decisions?” Dr. Howard said. “There is a lot of secrecy occurring at the regulatory body right now.”

Overall, he stated, “the FDA seems to be moving towards less stringent rules of all drugs, except for shots.”

Documented Track Record on Immunizations

Regarding immunizations, Høeg has a more established, if troubling, history, critics observe. She authored a analysis using unconfirmed public submissions to estimate the rate of heart inflammation after COVID-19 immunization. She advised the Florida surgeon general Dr. Joseph Ladapo, who was said to have modified findings to indicate COVID-19 vaccines are riskier than they are.

Part of her “policy goals” for the current administration encompassed revising regulations for novel immunizations and ending “optional” vaccines, she remarked following the vote on a podcast. At the agency, Dr. Høeg has allegedly proposed excluding adolescent males from obtaining COVID-19 vaccinations.

“She’s an thorough true believer who commences with her beliefs and works backwards to retrofit the evidence in a highly deceptive, dishonest manner,” Howard said.

Taking Control and a “Push for Payback”

Dr. Høeg aligned with other contrarians, {like|